WO2026069235 - TREATMENTS FOR INFLAMMATION
National phase entry is expected:
Publication Number
WO/2026/069235
Publication Date
02.04.2026
International Application No.
PCT/IB2025/059738
International Filing Date
26.09.2025
Title **
[English]
TREATMENTS FOR INFLAMMATION
[French]
TRAITEMENTS POUR L'INFLAMMATION
Applicants **
AUCKLAND UNISERVICES LIMITED
Inventors
SHOME, Avik
MUGISHO, Odunayo Omolola
RUPENTHAL, Ilva D.
Priority Data
63/700,527
27.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3757 | |
| EPO | Filing, Examination, Granting | 26134 | |
| Japan | Filing, Examination, Granting | 2805 | |
| South Korea | Filing, Examination, Granting | 3404 | |
| USA | Filing, Examination, Granting | 8210 |
Total:
44,310
Contact Us
Abstract[English]
The inventions relate to compounds, compositions and kits comprising connexin hemichannel modulators, inflammasome modulators, and/or pannexin channel modulators and new and improved methods comprising systemic and topical administration of such modulators for the treatment of ocular and dermatological diseases, disorders and conditions, including ocular and dermatological diseases, disorders and conditions characterized at least in part by inflammasome-mediated inflammation.[French]
La présente invention concerne des composés, des compositions et des kits comprenant des modulateurs d'hémicanaux de connexine, des modulateurs d'inflammasome et/ou des modulateurs de canaux de pannexine, ainsi que des méthodes novatrices et améliorées comprenant l'administration systémique et topique de ces modulateurs pour le traitement de maladies, troubles et affections oculaires et dermatologiques, notamment les maladies, troubles et affections oculaires et dermatologiques caractérisés, au moins en partie, par une inflammation médiée par l'inflammasome.